title: Fractalkine (CX3CL1): a biomarker reflecting symptomatic severity in patients with knee osteoarthritis.
abstract: BACKGROUND
  Elevated serum and synovial fluid (SF) fractalkine (CX3CL1) levels have been detected in patients with knee osteoarthritis (OA). The current study was carried out to investigate the association between serum and SF fractalkine levels with symptomatic severity in patients with knee OA.
  
  
  METHODS
  One hundred ninety-three patients with OA and 182 healthy controls were enrolled in this study. The symptomatic severity was assessed by the Western Ontario McMaster University Osteoarthritis scores.
  
  
  RESULTS
  Fractalkine levels in SF and serum were both positively associated with self-reported greater pain and physical disability.
  
  
  CONCLUSIONS
  Fractalkine in SF and serum may serve as a biomarker for reflecting symptomatic severity. Therapeutic interventions that target fractalkine signaling pathways to delay OA-related symptoms deserve further study.
authors.affiliation: From the Guangzhou Orthopedic Hospital, Guangzhou, China.
authors.forename: Li Wei
authors.initials: LW
authors.lastname: Huo
authors.forename: Yong Liang
authors.initials: YL
authors.lastname: Ye
authors.forename: Guang Wei
authors.initials: GW
authors.lastname: Wang
authors.forename: Yong Guang
authors.initials: YG
authors.lastname: Ye
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D054428:Chemokine CX3CL1 / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020370:Osteoarthritis, Knee / Q000097:blood* / Q000175:diagnosis*; D012720:Severity of Illness Index; D013582:Synovial Fluid / Q000378:metabolism*
chemical_list: D015415:Biomarkers; C515538:CX3CL1 protein, human; D054428:Chemokine CX3CL1